NASDAQ : LRMR
Larimar Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.67 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 278.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Details
| Name | Larimar Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 71 |
| Ceo | Carole Ben-Maimon |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US5171251003 |
| Cusip | 517125100 |
| Cik | 1374690 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | Chief Executive Officer and Director |
| Michael Celano CPA | Secretary and Chief Financial Officer |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer |
| John B. Harlow Jr. | President and Chief Operating Officer |
| John Berman | Vice President of Finance and Administration |
| Jennifer Spokes Johansson | Vice President of Legal and Compliance |
| Dr. Russell G. Clayton Sr., D.O. | Chief Medical Officer |
| Francis Michael Conway CPA | Vice President and Controller |
Contact
| Address | Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania 19004, United States |
| Phone | 844 511 9056 |
| Website | https://www.larimartx.com |